Company news
Journey Medical Corporation news in 2025
Journey Medical Corporation's news releases, calls and decks from 2025, newest first.
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
December 11, 2025
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
December 10, 2025
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 12, 2025
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
November 5, 2025
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
October 24, 2025
Journey Medical Corporation to Participate in October 2025 Investor Conferences
October 8, 2025
Journey Medical Corporation to Participate in September 2025 Investor Conferences
September 3, 2025
Journey Medical Corporation to Present at the Emerging Growth Conference
August 18, 2025
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
August 12, 2025
Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
August 7, 2025
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
August 5, 2025
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
July 14, 2025
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
June 24, 2025
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
June 20, 2025
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
June 9, 2025
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
May 14, 2025
Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
May 7, 2025
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
April 1, 2025
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
March 26, 2025
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
March 24, 2025
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
March 19, 2025
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
March 12, 2025
Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
March 5, 2025
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
March 4, 2025
Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
January 22, 2025
Calls in 2025
Decks in 2025
- Q1 2025 Earnings Presentation
Earnings · 28 slides · May 14, 2025
- Corporate Update (February 2025)
Corporate update · 36 slides · Feb 5, 2025